Charles B. Nguyen, M.D.

877-541-4673
Charles B. Nguyen, M.D.
Medical Oncologist
Clinical Expertise
  • Kidney Cancer
  • Bladder Cancer
  • Prostate Cancer
  • Testicular Cancer
  • Clinical Trials
Research Area
  • Biomarker Development in Genitourinary Cancers
Other Languages Spoken
Vietnamese
Academic Appointments
  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Medical Oncology & Therapeutics Research
Genitourinary Cancers
Hematology

Charles B. Nguyen, M.D. is a nationally recognized medical oncologist with interests in clinical trials, clinicogenomics, and genitourinary cancers. Dr. Nguyen’s clinical trial work includes the phase 2 FORTUNE study in non-clear cell kidney cancer. He has published widely in peer-reviewed journals such as the Journal of Clinical Oncology Precision Oncology and Clinical Cancer Research. He has also presented his work at national conferences such as ASCO.

Dr. Nguyen most recently completed a hematology/oncology fellowship at the University of Michigan in Ann Arbor. Prior to this, he obtained his medical degree from the University of Oklahoma College of Medicine, followed by an internal medicine residency at Baylor College of Medicine.

Earning extensive honors for his work, Dr. Nguyen was selected for the 2022 ASCO/AACR Methods in Clinical Cancer Research workshop and received the V.A. Outstanding Graduating Resident in Inpatient Medicine award. Additionally, he was awarded the Professional Educator Appreciation and Recognition (PEAR) Award and membership in the Gold Humanism Honor Society. Dr. Nguyen is fluent in Vietnamese.

Location

Education & Experience

Board Certifications

  • 2024, American Board of Internal Medicine, Oncology

Degrees

  • 2018, Doctor of Medicine, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

Fellowship

  • 2021–2024, Hematology/Oncology, University of Michigan, Ann Arbor, Michigan

Residency

  • 2018–2021, Internal Medicine, Baylor College of Medicine, Houston, Texas

Professional Experience

  • 2024–present, Assistant Clinical Professor, City of Hope Orange County; Irvine, California

Publications

  • Nguyen CB, Oh E, Bahar P, Vaishampayan UN, Else, T, and Alva AS. Novel approaches with HIF-2α targeted therapies in metastatic renal cell carcinoma. Cancers (Basel). 2024; DOI:10.3390/cancers16030601.
  • Nguyen CB, Knaus C, Li J, Accardo ML, Koeppe E, Vaishampayan UN, Alva AS, Else T. Pathogenic germline mutational landscape in patients with renal cell carcinoma and associated clinicopathologic features. JCO Precision Oncology. 2023; DOI: 10.1200/PO.23.00168.
  • Nguyen CB, Kobe C, Kumbier KE, Bauman J, Burns JA, Tsao PA, Sparks JB, Skolarus TA, Caram MEV. Determinants of bone modifying agent prescribing for metastatic castration-resistant prostate cancer in a national healthcare delivery system. JCO Oncology Practice. 2023; 20(1):59-68.
  • Nguyen CB and Alva AS. The future of radioligand therapies in metastatic castrate-resistant prostate cancer. Advances in Oncology. 2023; doi: 10.1016/j.yao.2023.01.009
  • Tsung I, Green E, Palmbos P, Sloan Z, Reichert ZR, Vaishampayan U, Smith DC, Caram MEV, Yentz S, Daignault-Newton S, Hurley M, Nguyen CB, Kraft S, Alva A. A phase 2 trial of nab-paclitaxel in combination with anti-PD1 therapy in advanced urothelial cancer. Journal of Urology. 2022; 209(1):121-130.
  • Nguyen CB, Su CT, Morgan M, Alva AS. Case report: immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma. Frontiers in Oncology. 2022; doi:10.3389/fonc.2022.1000023.
  • Nguyen CB, Li M, Verstovsek G, Sen U, Swierenga C, Huang Q, Rivero G, Yellapragada SV. Primary bone lymphoma of the ilium successfully treated without radiation. Clinical Case Reports. 2020; 8(12):3130-3133.
  • Ali N, Nguyen CB, Chandrakesan P, Wolf RF, Qu D, May R, Goretsky T, Fazili J, Barrett TA, Li M, Huycke MM, Bronze MS, Houchen CW. Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical beta-catenin-dependent mechanism. Scientific Reports. 2020; 10(1):10578.
  • Li M, Nguyen CB, Yeung Z, Sanchez K, Bushan S. Evans syndrome in a patient with COVID-19. British Journal of Haematology. 2020; 190(2):e59-e61.
  • Nguyen CB, Houchen CW, Ali N. Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Experimental Biology and Medicine. 2017; 242(3):242-249.
  • Nguyen CB, Kotturi H, Waris G, Mohammed A, Chandrakesan P, May R, Sureban S, Weygant N, Qu D, Rao CV, Dhanasekaran DN, Bronze MS, Houchen CW, Ali N. (Z)-3,5,4’-trimethoxystilbene limits hepatitis C and cancer pathophysiology by blocking microtubule dynamics and cell-cycle progression. Cancer Research. 2016; 76(16):4887-4896.
  • Ali N., Chandrakesan P, Nguyen CB, Husain S, Gillaspy AF, Huycke M, Berry WL, May R, Qu D, Weygant N, Sureban SM, Bronze MS, Dhanasekaran DN, Houchen CW. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget. 2015; 6(24): 20327-20344.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Recommend this provider office
5.0
Provider listen carefully to you
5.0
Show respect for what you say
5.0
Spend enough time with you
4.9
Provider explain in way you understand
4.9
Know important info medical history
4.9
Rate provider 0-10
03/27/26
Dr. Nguyen is top notch! He explains everything in a way that's easy to understand. He is very easy to talk to and you can tell he cares about your care plan. Highly recommended! - Verified patient
02/17/26
MD Nguyen. Excellent physician, in all ways - Verified patient
02/17/26
Wonderfull in everyway, very happy in all they do - Verified patient
02/16/26
Excellent! - Verified patient
02/09/26
Your facility, doctors and nurses are outstanding! Thank you for your service! - Verified patient